Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
Applied Microbiology and Biotechnology · 2024-12 · 108 (1)
DOI: 10.1007/s00253-023-12927-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 27.01.2024. Verfasst von Jacquelynne Cervantes-Torres und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine, Universidad Nacional Autónoma de México, Coyoacán, 04510, Mexico City, Mexico. Hauptthemen laut MEDLINE: Adenovirus Vaccines, COVID-19, Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UNAM Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica, UNAM Instituto de Investigaciones Biomedicas.
Abstract (Originalsprache)
Several COVID-19 vaccines use adenovirus vectors to deliver the SARS-CoV-2 spike (S) protein. Immunization with these vaccines promotes immunity against the S protein, but against also the adenovirus itself. This could interfere with the entry of the vaccine into the cell, reducing its efficacy. Herein, we evaluate the efficiency of an adenovirus-vectored vaccine (chimpanzee ChAdOx1 adenovirus, AZD1222) in boosting the specific immunity compared to that induced by a recombinant receptor-binding domain (RBD)-based vaccine without viral vector. Mice immunized with the AZD1222 human vaccine were given a booster 6 months later, with either the homologous vaccine or a recombinant vaccine based on RBD of the delta variant, which was prevalent at the start of this study. A significant increase in anti-RBD antibody levels was observed in rRBD-boosted mice (31–61%) compared to those receiving two doses of AZD1222 (0%). Significantly higher rates of PepMix™- or RBD-elicited proliferation were also observed in IFNγ-producing CD4 and CD8 cells from mice boosted with one or two doses of RBD, respectively. The lower efficiency of the ChAdOx1-S vaccine in boosting specific immunity could be the result of a pre-existing anti-vector immunity, induced by increased levels of anti-adenovirus antibodies found both in mice and humans. Taken together, these results point to the importance of avoiding the recurrent use of the same adenovirus vector in individuals with immunity and memory against them. It also illustrates the disadvantages of ChAdOx1 adenovirus-vectored vaccine with respect to recombinant protein vaccines, which can be used without restriction in vaccine-booster programs. Key points • ChAdOx1 adenovirus vaccine (AZD1222) may not be effective in boosting anti-SARS-CoV-2 immunity • A recombinant RBD protein vaccine is effective in boosting anti-SARS-CoV-2 immunity in mice • Antibodies elicited by the rRBD-delta vaccine persisted for up to 3 months in mice
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Veterinary Medicine, Universidad Nacional Autónoma de México, Coyoacán, 04510, Mexico City, Mexico.
- Biomedical Research Institute, Universidad Nacional Autónoma de México, Coyoacán, 04510, Mexico City, Mexico.
- Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Belisario Domínguez Secc. 16, Tlalpan, 14080, Mexico City, CDMX, Mexico.
- Laboratorio Nacional de Citometría de Flujo, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Coyoacán, 04510, Mexico City, Mexico.
- Unidad de Experimentación Preclínica, Facultad de Química, Universidad Nacional Autónoma de México, Coyoacán, 04510, Mexico City, Mexico.
- Unidad de Desarrollo e Investigación en Bioterapeúticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, 11340, Mexico City, Mexico.
Förderung
- UNAM Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica
- UNAM Instituto de Investigaciones Biomedicas
Zitieren
APA
Cervantes-Torres, J., Cabello-Gutiérrez, C., Ayón-Núñez, D. A., Soldevila, G., Olguin-Alor, R., Diaz, G., Acero, G., Segura-Velázquez, R., Huerta, L., Gracia-Mora, I., Cobos, L., Pérez-Tapia, M., Almagro, J. C., Suárez-Güemes, F., Bobes, R. J., Fragoso, G., Sciutto, E., & Laclette, J. P. (2024). Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice. Applied Microbiology and Biotechnology, 108(1). https://doi.org/10.1007/s00253-023-12927-0
Vancouver
Cervantes-Torres J, Cabello-Gutiérrez C, Ayón-Núñez DA, Soldevila G, Olguin-Alor R, Diaz G, et al. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice. Applied Microbiology and Biotechnology. 2024;108(1). doi:10.1007/s00253-023-12927-0
BibTeX
@article{CervantesTorres2024,
author = {Cervantes-Torres, Jacquelynne and Cabello-Gutiérrez, Carlos and Ayón-Núñez, Dolores-Adriana and Soldevila, Gloria and Olguin-Alor, Roxana and Diaz, Georgina and Acero, Gonzalo and Segura-Velázquez, René and Huerta, Leonor and Gracia-Mora, Isabel and Cobos, Laura and Pérez-Tapia, Mayra and Almagro, Juan C and Suárez-Güemes, Francisco and Bobes, Raúl J and Fragoso, Gladis and Sciutto, Edda and Laclette, Juan Pedro},
title = {Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
volume = {108},
number = {1},
doi = {10.1007/s00253-023-12927-0}
}
EUVIMED